10,730,210 (as of 11/9/2023)
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to commercializing innovative products to address unmet needs in women's sexual and reproductive health.
The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.
The U.S. contraceptive market was estimated at $8.3 billion as of 2022. Every 1% market share of the 43.3 million women in our addressable market represents more than $300 million in net product sales for Evofem.
Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.
Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". From May 18, 2023, until June 20, 2023, it traded under the ticker symbol "EVFMD," then reverted to the ticker symbol "EVFM".